Sugi Predict

Sugi Predict / Compounds / SCHEMBL15067679

SCHEMBL15067679

SCHEMBL15067679

O=[N+]([O-])c1ccc(Oc2ccccc2)c(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.53
▸ MEN1 O00255 5/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ LMNA P02545 3/20 0.53
▸ CYP19A1 P11511 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ MLNR O43193 1/20 0.53
▸ MMP1 P03956 1/20 0.53
▸ MPO P05164 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ ADORA3 P0DMS8 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ TBXA2R P21731 1/20 0.53
▸ PTGS1 P23219 1/20 0.53
▸ SLC6A2 P23975 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29683621 0.86 HSPB1 (0.49) MAPTMEN1KMT2ALMNAGLA
SCHEMBL21904820 0.84 HSPB1 (0.71) MAPTMEN1KMT2ALMNATBXA2R
SCHEMBL31395357 0.84 HSPB1 (0.71) MAPTMEN1KMT2ALMNATBXA2R
SCHEMBL20155482 0.84 PDE7A (0.57) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL21905001 0.84 MEN1 (0.51) MAPTMEN1KMT2ALMNATBXA2R
SCHEMBL11094243 0.84 ALDH1A1 (0.53) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7813399 0.82 MEN1 (0.72) MAPTMEN1KMT2ALMNACYP19A1
SCHEMBL5214063 0.81 MAPT (0.57) MAPTMEN1KMT2ALMNACYP19A1
SCHEMBL21652814 0.81 MEN1 (0.48) MAPTMEN1KMT2ATBXA2RSLC6A2
SCHEMBL21633970 0.81 PTGS2 (0.48) MAPTMEN1KMT2ALMNACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030880-B2 Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-07-09 — — US disclosed
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 — — US disclosed
CN-110167939-B Pyrrolo [2,3-c ] pyridine derivatives, preparation method and medical application thereof 江苏豪森药业集团有限公司 2021-12-31 — — CN disclosed
US-20210236508-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-08-05 — — US disclosed
CN-106986872-B Bromodomain inhibitors 艾伯维公司 2020-04-21 — — CN disclosed
US-20180296566-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-18 — — US disclosed
WO-2018130174-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 江苏豪森药业集团有限公司 2018-07-19 — — WO disclosed
EP-2858990-B1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC (US) 2018-05-16 — — EP disclosed
EP-2797918-B1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2017-11-29 — — EP disclosed
US-9561231-B2 Pyridinone and pyridazinone derivatives ABBVIE INC. (US) 2017-02-07 — — US disclosed
EP-2858990-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES AbbVie Inc. (US) 2015-04-15 — — EP disclosed
EP-2797918-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2014-11-05 — — EP disclosed
WO-2014164771-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-10-09 — — WO disclosed
US-20140256705-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-09-11 — — US disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 — — US disclosed
WO-2013185284-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBOTT LABORATORIES (US) 2013-12-19 — — WO disclosed
WO-2013188381-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC. (US) 2013-12-19 — — WO disclosed
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives ABBVIE INC. 2013-12-12 — — US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 — — WO disclosed
WO-2013097052-A1 BROMODOMAIN INHIBITORS ABBOTT LABORATORIES (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296566-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPT 2252/4885MEN1 516/4885KMT2A 405/4885
US-12030880-B2 Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof BRD4, BRD1, BRD3 MAPT 1460/4885MEN1 2445/4885KMT2A 906/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPT 2252/4885MEN1 516/4885KMT2A 405/4885
US-20140256705-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 MAPT 1922/4885MEN1 948/4885KMT2A 238/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPT 2252/4885MEN1 516/4885KMT2A 405/4885
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives CYP4F3, CYP4B1, CYP4F11 MAPT 4393/4885MEN1 1697/4885KMT2A 3853/4885
US-20210236508-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPT 2252/4885MEN1 516/4885KMT2A 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.